Clinical screening assay for EGFR exon 19 mutations using PNA-clamp smart amplification process version 2 in lung adenocarcinoma

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1213-1219

  Araki, Takuya ^a,b   Shimizu, Kimihiro ^a   Nakamura, Tomonori ^a,b   Baba, Masaru ^c,d   Kawai, Yuki ^c,d   Nakamura, Katsunori ^a   Mitani, Yasumasa ^c,d   Obayashi, Kyoko ^b   Aomori, Tohru ^b   Fujita, Yukiyoshi ^b   Miyamae, Yohei ^a   Kakegawa, Seiichi ^a   Kaira, Kyoichi ^a   Lezhava, Alexander ^d   Hayashizaki, Yoshihide ^d   Takeyoshi, Izumi ^a   Yamamoto, Koujirou ^a,b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c KK DNAFORM   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

EGFR mutation; Non small cell lung cancer; PNA clamp SmartAmp2

Indexed keywords

DNA; GEFITINIB; PEPTIDE NUCLEIC ACID;

ARTICLE; CLINICAL ASSESSMENT TOOL; CODON; CONTROLLED STUDY; DNA SEQUENCE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; GENE DELETION; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MUTATIONAL ANALYSIS; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RECEPTOR GENE; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; BASE SEQUENCE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; EXONS; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80053166271     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1391     Document Type: Article

References (34)

1. Cohen MH, Williams GA, Sridhara R, et al: United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218, 2004.
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
3. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
4. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203, 2004.
5. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
6. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinico- pathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005.
7. Asano H, Toyooka S, Tokumo M, et al: Detection of EGFR gene mutation in lung cancer by mutant enriched polymerase chain reaction assay. Clin Cancer Res 12: 43-48, 2006.
8. Cohen V, Agulnik JS, Jarry J, et al: Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in non-small cell lung cancer. Cancer 107: 2858-2865, 2006.
9. Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384, 2005.
10. Jänne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12: 751-758, 2006.
11. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B and Nishio K: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
12. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K and Nishio K: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 97: 642-648, 2006.
13. Lin CH, Yeh KT, Chang YS, Hsu NC and Chang JG: Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. J Biomed Sci 12: 37-42, 2010.
14. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treat-ment. J Clin Oncol 23: 857-865, 2005.
15. Minarik M, Gassman M, Belsanova B, et al: A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA. Electrophoresis 31: 3518-3524, 2010.
16. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.
17. Nomoto K, Tsuta K, Takano T, et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615, 2006.
18. Oshita F, Matsukuma S, Yoshihara M, et al: Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a signi-ficant correlation to gefitinib efficacy in non-small cell lung cancer. Br J Cancer 95: 1070-1075, 2006.
19. Pan Q, Pao W and Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7: 396-403, 2005.
20. Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11: 2924-2929, 2005.
21. Thomas RK, Nickerson E, Simons JF, et al: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12: 852-855, 2006.
22. Willmore-Payne C, Holden JA and Layfield LJ: Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol 37: 755-763, 2006.
23. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 8: 335-341, 2006.
24. Yu J, Kane S, Wu J, et al: Mutation-specific antibodies for the detection of EGFR mutations in non-small cell lung cancer. Clin Cancer Res 15: 3023-3028, 2009.
25. Zhou C, Zhao Y and Su B: Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. Cancer J 12: 33-39, 2006.
26. Mitani Y, Lezhava A, Kawai Y, et al: Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat Methods 4: 257-262, 2007.
27. Araki T, Shimizu K, Nakamura K, et al: Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon12 mutations in lung adenocarcinoma. Comparison of PNA-clamp SmartAmp2 and polymerase chain reaction-related methods. J Mol Diagn 12: 118-124, 2009.
28. Hoshi K, Takakura H, Mitani Y, et al: Rapid detection of epidermal growth factor receptor mutations in lung cancer by the Smart-amplification process. Clin Cancer Res 13: 4974-4983, 2007.
29. Cao W, Hashibe M, Rao JY, Morgenstern H and Zhang ZF: Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. Cancer Detect Prev 27: 397-404, 2003.
30. Miyamae Y, Shimizu K, Mitani Y, et al: Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn 12: 257-264, 2010.
31. Ji H, Li D, Chen L, et al: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495, 2006.
32. Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377, 2008.
33. Otani H, Toyooka S, Soh J, et al: Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. J Thorac Oncol 3: 472-476, 2008.
34. Soh J, Toyooka S, Aoe K, et al: Usefulness of EGFR mutation screening in pleural fluorescent substance fluid to predict the clinical outcome of gefitinib-treated patients with lung cancer. Int J Cancer 119: 2353-2358, 2006.